Valuation: Beta Bionics, Inc.

Market Cap 744M 653M 601M 560M 1.06B 70.75B 1.08B 7.23B 2.8B 34.73B 2.79B 2.73B 121B P/E 2026 *
-7.53x
P/E 2027 * -7.59x
Enterprise Value 570M 500M 461M 429M 809M 54.19B 826M 5.54B 2.15B 26.6B 2.14B 2.09B 92.57B EV / Sales 2026 *
4.26x
EV / Sales 2027 * 3.57x
Free-Float
98.9%
Yield 2026 *
-
Yield 2027 * -
1 day+6.57%
1 week+13.37%
Current month+6.57%
1 month+30.47%
3 months+66.83%
6 months-45.19%
Current year-45.19%
1 week 15.51
Extreme 15.51
17.18
1 month 12.26
Extreme 12.26
17.18
Current year 8.8
Extreme 8.8
32.58
1 year 8.8
Extreme 8.8
32.71
3 years 8.8
Extreme 8.8
32.71
5 years 8.8
Extreme 8.8
32.71
10 years 8.8
Extreme 8.8
32.71
Manager TitleAgeSince
Chief Executive Officer 50 15/08/2022
Director of Finance/CFO 37 01/08/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 57 01/02/2020
Director/Board Member 62 26/03/2025
Director/Board Member 63 01/10/2024
Date Insider Type Main position Quantity % Market Cap.
06-29Fiscal year

Chief Financial Officer

14,688 0.0330%
06-24Sell

Executive/Senior Manager

-1,258 0.0028%
06-04Sell

Executive/Senior Manager

-275 0.0006%
Change 5-day change 1-year change 3-year change Capi.($)
+6.57%+13.37%+19.80% - 744M
+2.39%+4.29%+21.80%-1.61% 191B
+1.18%+0.14%-25.21%+17.68% 143B
+1.70%+2.57%-3.67%-19.28% 137B
+0.89%-3.15%-58.90%-20.39% 64B
+1.69%+2.60%+19.19%-2.48% 52.97B
-0.81%+0.73%-26.51%-33.51% 43.82B
+0.42%+1.34%+10.74%+10.93% 37.67B
+0.82%+2.42%+5.91%+41.87% 37.13B
+1.33%-0.03%-14.60%-20.16% 29.5B
Average +1.60%+3.47%-5.15%-3.00% 73.62B
Weighted average by Cap. +1.43%+3.38%-4.95%-2.67%

Financials

2026 *2027 *
Net sales 134M 117M 108M 101M 190M 12.71B 194M 1.3B 503M 6.24B 502M 491M 21.71B 181M 159M 146M 136M 257M 17.19B 262M 1.76B 681M 8.44B 679M 664M 29.36B
Net income -99.27M -87.16M -80.23M -74.76M -141M -9.44B -144M -965M -374M -4.63B -373M -365M -16.12B -98.46M -86.44M -79.57M -74.14M -140M -9.36B -143M -957M -371M -4.59B -370M -362M -15.99B
Net Debt -174M -153M -141M -131M -247M -16.56B -252M -1.69B -656M -8.13B -654M -640M -28.3B -97.89M -85.94M -79.11M -73.72M -139M -9.31B -142M -951M -369M -4.57B -368M -360M -15.9B
Logo Beta Bionics, Inc.
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
Employees
422
Date Price Change Volume
01/07/26 $16.70 +6.57% 787,411
30/06/26 $15.67 -7.82% 931,679
29/06/26 $17.00 +1.07% 715,562
26/06/26 $16.82 +5.72% 2,041,708
25/06/26 $15.91 +8.01% 1,093,074
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
16.70USD
Average target price
19.18USD
Spread / Average Target
+14.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BBNX Stock